Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 6, 2003, Pages 1842-1852

  Seignères, Béatrice ^a   Martin, Perrine ^a   Werle, Bettina ^a   Schorr, Olivier ^a   Jamard, Catherine ^a   Rimsky, Laurence ^b   Trépo, Christian ^a   Zoulim, Fabien ^a  

^a INSERM   (France)

^b Triangle Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; AMDOXOVIR; CIRCULAR DNA; CLEVUDINE; EMTRICITABINE; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS DNA;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFICACY; DUCK; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS B VIRUS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BLOTTING, SOUTHERN; CELL SURVIVAL; DEOXYCYTIDINE; DIOXOLANES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DUCKS; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS, DUCK; HEPATITIS B, CHRONIC; HEPATITIS, VIRAL, ANIMAL; HEPATOCYTES; POLYMERASE CHAIN REACTION; PURINE NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 0038102266     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.6.1842-1852.2003     Document Type: Article

References (44)

1. Aguesse-Germon, S., S. H. Liu, M. Chevallier, C. Pichoud, C. Jamard, C. Borel, C. K. Chu, C. Trépo, Y. C. Cheng, and F. Zoulim. 1998. Inhibitory effect of 2′-fluoro-5-methyl-β-L-arabinofuranosyl-uracil on duck hepatitis B virus replication. Antimicrob. Agents Chemother. 42:369-376.
2. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. J. Tyrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
3. Borel, C., O. Schorr, I. Durand, F. Zoulim, A. Kay, C. Trepo, and O. Hantz. 2001. Initial amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of embryonic duck hepatocytes is increased by cell cycle progression. Hepatology 34:168-179.
4. Chayama, K., Y. Suzuki, M. Kobayashi, M. Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyamo, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saito, N. Murashima, K. Ikeda, and H. Kumada. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
5. Chin, R., T. Shaw, J. Torresi, V. Sozzi, C. Trautwein, T. Bock, M. Manns, P. Furman, and S. Locarnini. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45:2495-2501.
6. Chow, Y. K., M. S. Hirsch, D. P. Merrill, L. J. Bechtel, J. J. Eron, J. C. Kaplan, and R. T. D'Aquila. 1993. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361:650-654.
7. Colledge, D., G. Civitico, S. Locarnini, and T. Shaw. 2000. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob. Agents Chemother. 44:551-560.
8. Colledge, D., S. Locarnini, and T. Shaw. 1997. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 26:216-225.
9. Cullen, J. M., S. L. Smith, M. G. Davis, S. E. Dunn, C. Botteron, A. Cecchi, D. Linsey, D. Linzey, L. Frick, M. T. Paff, A. Goulding, and K. Biron. 1997. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob. Agents Chemother. 41:2076-2082.
10. Das, K., X. Xiong, H. Yang, C. E. Westland, C. S. Gibbs, S. G. Sarafianos, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75:4771-4779.
11. Delmas, J., O. Schorr, C. Jamard, C. Gibbs, C. Trepo, O. Hantz, and F. Zoulim. 2002. Inhibitory effect of adefovir on viral DNA synthesis and CCC DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob. Agents Chemother. 46:425-433.
12. de Man, R. A., L. M. Wolters, F. Nevens, D. Chua, M. Sherman, C. L. Lai, A. Gadano, Y. Lee, F. Mazzotta, N. Thomas, and D. DeHertogh. 2001. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 34:578-582.
13. Gish, R. G., N. W. Y. Leung, T. L. Wright, H. Trinh, W. Lang, H. A. Kessler, L. Fang, L. H. Wang, J. Delehanty, A. Rigney, E. Mondou, A. Snow, and F. Rousseau. 2002. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemother. 46:1734-1740.
14. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
15. Hantz, O., C. Borel, C. Trabaud, F. Zoulim, J. Dessolin, M. Camplo, P. Vlieghe, M. Bouygues, C. Trépo, and J. L. Kraus. 1997. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob. Agents Chemother. 41:2579-2581.
16. Hoofnagle, J. H., and A. M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
17. Jilbert, A. R., T. T. Wu, J. M. England, P. M. Hall, N. Z. Carp, A. P. O'Connell, and W. S. Mason. 1992. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 66:1377-1388.
18. Korba, B. E. 1996. In vitro evaluation of combination therapies against hepatitis B virus replication. Antivir. Res. 29:49-51.
19. Korba, B. E., P. Cote, W. Hornbuckle, R. Schinazi, J. L. Gerin, and B. C. Tennant. 2000. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antivir. Res. 45:19-32.
20. Korba, B. E., R. F. Schinazi, P. Cote, B. C. Tennant, and J. L. Gerin. 2000. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob. Agents Chemother. 44:1757-1760.
21. Krishnan, P., Q. Fu, W. Lam, J. Y. Liou, G. Dutschman, and Y. C. Cheng. 2002. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 277:5453-5459.
22. Krishnan, P., J. Y. Liou, and Y. C. Cheng. 2002. Phosphorylation of pyrimidine L-deoxynucleoside analog diphosphates. Kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 277:31593-31600.
23. Lai, C. L., R. W. Chine, N. W. Y. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and F. Gray. 1998. A one year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
24. Lee, W. M. 1997. Hepatitis B virus infection. N. Engl. J. Med. 337:1733-1745.
25. Leguerhier, F., C. Pichoud, S. Guerret, M. Chevallier, C. Jamard, O. Hantz, X. Y. Li, S. H. Chen, I. King, C. Trepo, Y. C. Cheng, and F. Zoulim. 2000. Characterization of the antiviral effect of 2′,3′-dideoxy-2′, 3′-didehydro-β-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 44:111-122.
26. Leung, N. W., C. L. Lai, T. T. Chang, R. Guan, C. M. Lee, K. Y. Ng, S. G. Lim, P. C. Wu, J. C. Dent, S. Edmundson, L. D. Condreay, and R. N. Chien. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
27. Liu, S.-H., K. L. Grove, and Y.-C. Cheng. 1998. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob. Agents Chemother. 42:833-839.
28. Marion, P. L., F. H. Salazar, M. A. Winters, and R. J. Colonno. 2002. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother. 46:82-88.
29. Mason, W., J. Cullen, J. Saputelli, T. Wu, C. Liu, W. London, E. Lustbader, P. Schaffer, A. O'Connell, I. Fourel, C. Aldrich, and A. Jilbert. 1994. Characterization of the antiviral activity of 2′carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 19:398-411.
30. Mason, W. S., J. Cullen, G. Moraleda, J. Saputelli, C. E. Aldrich, D. S. Miller, B. Tennant, L. Frick, D. Averett, L. D. Condreay, and A. R. Jilbert. 1998. Lamivudine therapy of WHV-infected woodchucks. Virology 245:18-32.
31. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
32. Nafa, S., S. Ahmed, D. Tavan, C. Pichoud, F. Berby, L. Stuyver, M. Johnson, P. Merle, H. Abidi, C. Trepo, and F. Zoulim. 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32:1078-1088.
33. Nowak, M., S. Bonhoeffer, A. Hill, R. Boehme, H. Thomas, and H. McDade. 1996. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93:4398-4402.
34. Ono, S. K., N. Kato, Y. Shiratori, J. Kato, T. Goto, R. F. Schinazi, F. J. Carrilho, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107:449-455.
35. Seignères, B., S. Aguesse-Germon, C. Pichoud, I. Vuillermoz, C. Jamard, C. Trépo, and F. Zoulim. 2001. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J. Hepatol. 34:114-122.
36. Seignères, B., C. Pichoud, S. S. Ahmed, O. Hantz, C. Trepo, and F. Zoulim. 2000. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J. Infect. Dis. 181:1221-1233.
37. Seignères, B., C. Pichoud, P. Martin, P. Furman, C. Trépo, and F. Zoulim. 2002. Inhibitory activity of dioxolane purine analogs on wild-type lamivudine-resistant mutants of hepadnaviruses. Hepatology 36:710-722.
38. Snyder, S., D. Z. D'Argenio, O. Weislow, J. A. Bilello, and G. L. Drusano. 2000. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob. Agents Chemother. 44:1051-1058.
39. Stuyver, L. J., S. A. Locarnini, A. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, R. F. Schinazi, and the HEP DART International Committee. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
40. Tsiang, M., J. F. Rooney, J. J. Toole, and C. S. Gibbs. 1999. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29:1863-1869.
41. Villahermosa, M. L., J. J. Martinez-Irujo, F. Cabodevilla, and E. Santiago. 1997. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry 36:13223-13231.
42. Zoulim, F. 2001. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models. Antivir. Chem. Chemother. 12(Suppl. 1):131-142.
43. Zoulim, F., E. Dannaoui, C. Borel, O. Hantz, T. S. Lin, S. H. Liu, C. Trépo, and Y. C. Cheng. 1996. 2′,3′-Dideoxy-β-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40:448-453.
44. Zoulim, F., J. Saputelli, and C. Seeger. 1994. Woodchuck hepatitis virus X protein is required for viral replication in vivo. J. Virol. 68:2026-2030.